AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

Medscape Medical News, October 30, 2024 Alert FDA OKs Novel Levodopa-Based Regimen for Parkinson’s Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa ...

Additionally, AbbVie Inc. (NYSE:ABBV)’s R&D efforts are progressing, with new approvals and studies underway, including Vyalev for Parkinson’s and Botox for platysma bands. The company also ...